Open AccessLenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study
Author(s) -
Fuqun Wei,
Qizhen Huang,
Jian He,
Liang Luo,
Yongyi Zeng
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s304820
Subject(s) - lenvatinib , medicine , hepatocellular carcinoma , adverse effect , oncology , sorafenib
Compared the outcomes between lenvatinib plus camrelizumab therapy and lenvatinib monotherapy as post-progression treatment for advanced hepatocellular carcinoma (HCC) with progressive disease (PD).